By Ed Silverman, Pharmalot Columnist
September 10, 2026
The pharmaceutical landscape is currently navigating a period of profound volatility, characterized by both high-stakes clinical disappointments and a shifting paradigm in how the federal government approaches the cost of medication. As we start this busy morning at the Pharmalot campus, the industry news cycle is dominated by two major developments: a brewing governance crisis at Swiss pharmaceutical giant Novartis and a significant expansion of the Trump administration’s drug-pricing strategy led by CMS Administrator Mehmet Oz.
I. The Novartis Crisis: Shareholder Activism Meets Clinical Failure
For Novartis, the week has been nothing short of a "perfect storm." Following a series of disappointing clinical trial results, the company’s share price has suffered a record decline, triggering an immediate and aggressive response from one of its most influential stakeholders.
The Call for Governance Reform
David Samra, the managing director at Artisan Partners and founding partner of the International Value Group, has officially called for a comprehensive shake-up of the Novartis board of directors. Samra’s critique strikes at the heart of the company’s strategic decision-making process. He explicitly stated that successive chairmen have failed to provide adequate oversight, particularly regarding the company’s aggressive acquisition strategy.
Artisan Partners, a significant shareholder, is pushing for a fundamental change in how Novartis approaches mergers and acquisitions (M&A). The core of the argument is that the current board has overseen a string of expensive, ill-fated bets that have eroded shareholder value rather than bolstering the company’s long-term pipeline.
The Catalyst: Failed Trials and Eroding Confidence
The investor revolt follows two major clinical setbacks that have sent shockwaves through the investment community:
- The Avidity Takeover: Novartis’s $12 billion acquisition of Avidity—a move intended to cement the drugmaker’s position in specialized therapies—has hit a significant wall. A key drug candidate targeting a muscle-wasting disorder recently failed its late-stage clinical trial, casting doubt on the entire valuation of the deal.
- Pelacarsen Disappointment: Simultaneously, data from the heart drug pelacarsen failed to meet investor expectations, further dampening sentiment around the company’s R&D capabilities.
II. Chronology of the Novartis Downfall
To understand the current crisis, one must look at the timeline of events that led to the recent market turbulence:
- Q1 2026: Novartis signals its intent to aggressively expand its footprint in rare diseases and specialized cardiovascular care, leading to the highly publicized $12 billion acquisition of Avidity.
- August 2026: Initial murmurs of concern emerge regarding the pace of Novartis’s R&D pipeline as internal projections for key assets are quietly adjusted downward.
- Early September 2026: The company confirms that the lead candidate from the Avidity acquisition has failed its pivotal Phase III trial.
- September 8, 2026: Results for pelacarsen are released, showing insufficient efficacy in primary endpoints.
- September 9-10, 2026: Novartis shares plummet to record lows. Artisan Partners issues its formal letter demanding a board shake-up, citing a pattern of systemic governance failure.
III. The Federal Shift: CMS Administrator Mehmet Oz and "Bespoke" Pricing
While Novartis grapples with internal strife, the broader regulatory environment is undergoing a transformation under the guidance of CMS Administrator Mehmet Oz. The administration is signaling a shift toward a "bespoke" drug-pricing model, diverging from traditional, one-size-fits-all legislative solutions.
The Strategy: Voluntary Agreements
According to recent reports, the Trump administration has successfully negotiated more than two dozen voluntary agreements with pharmaceutical companies. Administrator Oz has framed these deals as a triumph of private-public negotiation.
The mechanism of these agreements is complex and highly individualized. In exchange for relief from specific international trade tariffs, pharmaceutical companies are agreeing to two primary conditions:
- Domestic Price Adjustments: A commitment to lower the prices charged to public programs, such as Medicare and Medicaid, for specific essential medicines.
- International Price Alignment: A promise that new drugs will be launched in the United States at price points commensurate with what is paid in other developed nations.
The Implications of "Bespoke" Deals
This strategy represents a departure from the more confrontational legislative approaches seen in previous years. By tying drug pricing to trade policy (specifically tariff relief), the administration is leveraging executive branch powers to bypass the legislative gridlock often found in Congress.
However, critics argue that these voluntary agreements lack the transparency of formal regulatory frameworks. Without standardized rules, there is a risk that the "bespoke" nature of these deals could lead to uneven outcomes where some therapeutic categories receive preferential treatment over others based on the specific negotiating power of individual pharmaceutical firms.
IV. Supporting Data: The Cost of Clinical Failure
The recent failure of the Avidity asset is a stark reminder of the "innovation risk" inherent in the biopharmaceutical sector. When a $12 billion acquisition fails to produce a marketable asset, the ripple effects are felt across the entire market capitalization of the firm.
- R&D Expenditure: Novartis has been spending billions annually to maintain its top-tier status in the global pharmaceutical market.
- Market Cap Volatility: The recent 72-hour period saw a significant contraction in Novartis’s market value, reflecting a loss of confidence in the board’s ability to manage capital allocation.
- The "Pelacarsen" Gap: Industry analysts have noted that the failure of pelacarsen to impress the market further complicates the company’s roadmap for the next five years, as it leaves a gap in the company’s late-stage cardiovascular portfolio.
V. Official Responses and Industry Outlook
The pharmaceutical industry has been relatively quiet following the news of the Novartis board challenge, with most analysts observing the situation from the sidelines.
A spokesperson for Novartis issued a brief statement acknowledging the shareholder concerns: "The company takes all feedback from our investors seriously. We are committed to maximizing value for our shareholders and are currently reviewing our strategic priorities in light of recent trial data."
On the policy front, Administrator Mehmet Oz has remained bullish on the progress of his drug-pricing initiative. In a recent briefing, he noted that the administration is "actively working on additional agreements" and that the current model of voluntary cooperation is "yielding more significant results for the American taxpayer than years of stalled legislative debate."
VI. Implications: What This Means for the Future
For Corporate Governance
The Artisan Partners challenge to the Novartis board is likely to serve as a bellwether for the rest of the industry. As clinical trial costs soar and the success rate for new drugs remains stubbornly low, shareholders are becoming increasingly intolerant of "empire building" through massive M&A deals that fail to pay off. We expect to see more institutional investors demanding seats at the table and greater scrutiny of the "buy-to-grow" business model.
For Drug Pricing
The Trump administration’s reliance on tariff relief as a bargaining chip introduces a new variable into the pharma-political equation. If this model proves successful, we may see a permanent decoupling of drug pricing from traditional healthcare legislation. This could lead to a more volatile market where a company’s pricing strategy is inextricably linked to the geopolitical climate and trade agreements, creating a complex new layer of risk for pharmaceutical executives to manage.
As the morning coffee runs dry and the news cycle continues to evolve, one thing is clear: both the boardroom and the cabinet room are currently in flux. The coming weeks will likely determine whether Novartis can stave off a hostile restructuring and whether the administration’s bespoke pricing deals can stand up to the scrutiny of long-term economic analysis.
We will continue to monitor these developments as they unfold. For further analysis and real-time updates, keep a close watch on Pharmalot.
Disclaimer: This report is for informational purposes and does not constitute financial or legal advice. Please consult with professional advisors before making any investment decisions.
